Entrectinib (RXDX-101), a next-generation ALK inhibitor with additional activity against NTRK and ROS1 rearrangements, has been well-tolerated in several phase 1 clinical trials in patients with ROS1-fusion positive NSCLC[151]. This evidence concerns the gene ALK and non-small cell lung carcinoma.